Publications by authors named "E Gomperts"
Article Synopsis
- Doxorubicin, a vital cancer treatment, can cause significant heart damage, but using low levels of carbon monoxide (CO) has been shown to offer protection against this toxicity.
- Researchers developed a new oral liquid drug (HBI-002) that allows patients to easily self-administer CO during doxorubicin treatment, aiming to address the challenges associated with traditional CO delivery methods.
- In tests on mice, HBI-002 notably increased CO levels in the heart, reduced damage from doxorubicin, and enhanced the drug's effectiveness against tumors, indicating it could be a valuable addition to cancer therapy without harming cardiac function.*
Carbon monoxide (CO) at low, non-toxic concentrations has been previously demonstrated to exert anti-inflammatory protection in murine models of sickle cell disease (SCD). However CO delivery by inhalation, CO-hemoglobin infusion or CO-releasing molecules presents problems for daily CO administration. Oral administration of a CO-saturated liquid avoids many of these issues and potentially provides a platform for self-administration to SCD patients.
View Article and Find Full Text PDFCarbon monoxide protects the kidney through the central circadian clock and CD39.
Proc Natl Acad Sci U S A
March 2018
Ischemia reperfusion injury (IRI) is the predominant tissue insult associated with organ transplantation. Treatment with carbon monoxide (CO) modulates the innate immune response associated with IRI and accelerates tissue recovery. The mechanism has been primarily descriptive and ascribed to the ability of CO to influence inflammation, cell death, and repair.
View Article and Find Full Text PDFIntroduction: Trenonacog alfa (IB1001) is a recombinant factor IX (rFIX) manufactured in Chinese hamster ovary (CHO) cells. IB1001 was evaluated in a multicentre clinical trial with haemophilia B patients.
Aim: The aim was to establish IB1001 pharmacokinetic non-inferiority to comparator rFIX, safety and efficacy in previously treated patients (PTPs) with haemophilia B.
Sickle Cell Disease (SCD) is a painful, lifelong hemoglobinopathy inherited as a missense point mutation in the hemoglobin (Hb) beta-globin gene. This disease has significant impact on quality of life and mortality, thus a substantial medical need exists to reduce the vaso-occlusive crises which underlie the pathophysiology of the disease. The concept that a gaseous molecule may exert biological function has been well known for over one hundred years.
View Article and Find Full Text PDF